Other Information
−Removed: As disclosed in the table below, during the three months ended March 31, 2026, certain of our directors and/or executive officers adopted plans for trading arrangements intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act.
+Added: As disclosed in the table below, during the three months ended June 30, 2026, certain of our directors and/or executive officers adopted plans for trading arrangements intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act.
Name Position Date of Plan Adoption Scheduled End Date of Trading Arrangement (a)
Total Number of Securities to Be Sold Under the Plan
−Removed: 2/25/2026 12/30/2026 1,929
−Removed: Goldstein, M.D.
−Removed: 2/5/2026 11/30/2026 1,929
−Removed: Kathryn Guarini, Ph.D.
−Removed: 2/13/2026 2/5/2027 1,600
−Removed: Marion McCourt
−Removed: Executive Vice President, Commercial
−Removed: 2/17/2026 5/5/2027 6,989
+Added: Murphy, Ph.D Executive Vice President, Co-Chief Scientific Officer 5/7/2026 12/31/2027 84,000
(a) The trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed
5 unchanged sentences
101 Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"):
−Removed: (i) the registrant's Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025;
−Removed: (ii) the registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2026 and 2025;
−Removed: (iii) the registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2026 and 2025;
−Removed: (iv) the registrant's Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025;
+Added: (i) the registrant's Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025;
+Added: (ii) the registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and six months ended June 30, 2026 and 2025;
+Added: (iii) the registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2026 and 2025;
+Added: (iv) the registrant's Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025;
and (v) the notes to the registrant's Condensed Consolidated Financial Statements.
2 unchanged sentences
REGENERON PHARMACEUTICALS, INC.
−Removed: April 29, 2026 By:
+Added: July 30, 2026 By:
/s/ Christopher Fenimore
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.